Navigation Links
Idenix Pharmaceuticals to Present at Deutsche Bank's 2008 Biotech Boston Confab
Date:11/10/2008

CAMBRIDGE, Mass., Nov. 7 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present at Deutsche Bank's 2008 Biotech Boston Confab on Tuesday, November 11th at 9:40 a.m. ET.

The live and archived webcast of the presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
2. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
3. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
4. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
5. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
6. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
9. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):